Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Denticleless E3 ubiquitin protein ligase homolog (DTL), also widely known as CDT2, is a critical substrate-recruiting component of the CRL4 (Cullin 4-DDB1) E3 ubiquitin ligase complex. It plays an essential role in maintaining genomic integrity, regulating DNA replication, and coordinating cell cycle progression. By binding to proliferating cell nuclear antigen (PCNA) on chromatin, DTL targets key regulatory proteins—such as the replication licensing factor CDT1, the cyclin-dependent kinase inhibitor p21, and the histone methyltransferase SET8—for polyubiquitination and subsequent proteasomal degradation during the S phase and following DNA damage. This tightly regulated proteolysis prevents unscheduled origin firing and DNA re-replication, thereby safeguarding the genome. DTL is frequently overexpressed in various human malignancies, including gastric, breast, bladder, and hepatocellular cancers, where its upregulation promotes uncontrolled cell proliferation, chemoresistance, and poor clinical outcomes. Additionally, DTL has been implicated in Alzheimer's disease through aberrant neuronal cell cycle reentry, and in cardiovascular disease via the degradation of the cholesterol transporter ABCA1. While direct small-molecule inhibitors of DTL are not yet clinically established, its activity can be indirectly modulated by neddylation inhibitors like pevonedistat (MLN4924) or COP9 signalosome inhibitors, and its expression is downregulated by drugs such as colchicine.
Indirect inhibition of CRL4-Cdt2 via inhibition of NEDD8-activating enzyme (NAE) to block cullin neddylation, indirect inhibition via COP9 signalosome (CSN) inhibition, or downregulation of DTL expression and disruption of its interaction with substrates.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Denticleless E3 ubiquitin protein ligase homolog (DTL).